Clinical scenarios warranting consideration of GLP-1 therapy include: Type 2 diabetes management : Per ADA 2024 Standards of Care, GLP-1 RAs may be considered as initial therapy in patients with established atherosclerotic cardiovascular disease (ASCVD), high ASCVD risk, chronic kidney disease (CKD), or heart failure, or as add-on therapy when glycemic targets aren't met Established cardiovascular disease : Several GLP-1 receptor agonists have demonstrated cardiovascular risk reduction in patients with type 2 diabetes and established ASCVD Chronic kidney disease : While SGLT2 inhibitors are generally prioritized for CKD with type 2 diabetes when eGFR allows, GLP-1 RAs may provide complementary benefits Obesity with complications : When lifestyle interventions produce insufficient weight loss in patients with obesity-related comorbidities Important safety considerations include: Contraindications : Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2
If approved, these non-peptide GLP-1s would be taken orally, which could expand treatment options for people who prefer pills over injections
K c khi bn cha bc sang tui lo ha, vic s dng Vitamin C ni chung v kem dng m Vitamin C ni ring hng ngy cng s gip da c bo v tt hn v lun trong trng thi khe mnh, ti tr
The results of the MTT assay indicated that treatment of HuOCSCs with the IC50 concentration of anisomycin significantly inhibited cell proliferation, and the extent of this inhibition correlated positively with the treatment time (Figure 1A)
We recommend our Micronutrient Lab to assess levels of: Iron (including ferritin) Vitamin D Vitamin B12 Zinc Magnesium Folate Biotin This helps target supplementation appropriately and prevents compounding deficiency-driven shedding
Anat Rec (Hoboken)
